News | March 18, 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The company announced positive topline data from the Phase 3 ADorable-1 trial
The initiative comes through a collaboration with Asia’s oldest latex condom manufacturer
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The trial will enroll up to 42 patients in Finland across four cohorts
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Subscribe To Our Newsletter & Stay Updated
